

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,

Petitioner,

v.

NOVO NORDISK A/S,

Patent Owner.

---

Case No. IPR2023-00723

Patent No. 8,129,343

---

**DECLARATION OF JOHN BANTLE, M.D., IN SUPPORT OF PETITION  
FOR *INTER PARTES* REVIEW OF  
U.S. PATENT NO. 8,129,343**

---

## TABLE OF CONTENTS

	Page
I. Qualifications and Background.....	7
A. Education and Experience; Prior Testimony .....	7
B. Basis for Opinions and Materials Considered.....	10
C. Retention and Compensation .....	10
II. Summary of Opinions .....	10
III. Legal Standards.....	12
IV. Person of Ordinary Skill in the Art.....	13
V. The '343 Patent (Ex. 1001) and Its Claims .....	16
VI. Claim Construction.....	18
VII. Background on Diabetes and the use of GLP-1 Derivatives for the Treatment of Diabetes .....	19
A. Diabetes Generally.....	19
B. Diabetes Treatment.....	20
C. The Use of GLP-1 Derivatives to Treat Diabetes.....	23
D. Liraglutide Behaves like GLP-1 to Treat Diabetes.....	23
VIII. Scope and Content of the Prior Art.....	25
A. Bridon (Ex. 1014).....	26
B. Dong (Ex. 1013).....	29
C. Knudsen 2001 (Ex. 1011) .....	30
D. Knudsen 2004 (Ex. 1010) .....	34
E. Knudsen patent (U.S. Patent No. 6,268,343) (Ex. 1012).....	40
F. Additional Prior Art References and Knowledge.....	44
1. <i>Drucker</i> (Ex. 1068) .....	44
2. <i>Gutniak</i> (Ex. 1054).....	45
3. <i>Nauck</i> (Ex. 1056).....	46
4. <i>Orskov</i> (Ex. 1052).....	46
5. <i>U.S. Patent No. 5,512,549</i> (Ex. 1046) .....	47

**TABLE OF CONTENTS**  
(continued)

	<b>Page</b>
6. <i>U.S. Patent No. 6,284,727 (Ex. 1053)</i> .....	48
7. <i>WO 87/06941 (Ex. 1057)</i> .....	49
8. <i>WO 91/11457 (Ex. 1047)</i> .....	50
IX. Unpatentability of Claims 3 and 6 of the '343 Patent .....	51
A. A POSA Would Have Been Motivated to Design a GLP-1 Agonist with an Extended Half-Life.....	51
B. Claims 3 and 6 of the '343 Patent under Ground 1.....	54
1. <i>A skilled artisan would have been motivated by Knudsen             2004, the Knudsen patent, Dong, or Bridon to arrive at             the invention claimed in claims 3 and 6 of the '343 patent....</i>	54
2. <i>A skilled artisan would have had a reasonable             expectation of success of treating type 2 diabetes in a             subject with an effective amount of a semaglutide-             containing pharmaceutical composition recited in claims             3 and 6.....</i>	56
C. Claims 3 and 6 of the '343 Patent under Ground 2.....	61
D. Claims 3 and 6 of the '343 Patent under Ground 3.....	62
E. No Secondary Considerations Overcome <i>Prima Facie</i> Obviousness.....	65
1. <i>No unexpected results.....</i>	65
2. <i>A POSA would have known there was no long-felt, unmet             need for a GLP-1 receptor agonist treatment, nor was             there any skepticism in the art .....</i>	65
X. Reservation of Rights.....	66

## TABLE OF ABBREVIATIONS

Full Name of Cited Reference	Abbreviation
U.S. Patent No. 8,536,122	'122 patent
U.S. Patent No. 8,129,343	'343 patent
U.S. Patent No. 5,512,549	'549 patent
U.S. Patent No. 6,284,727	'727 patent
Baggio, <i>Glucagon-like Peptide 1 and Glucagon-like Peptide 2</i> , 18 BEST PRAC. & RSCH. CLINICAL ENDOCRINOLOGY & METABOLISM 531 (2004)	Baggio 2004b
Banting, <i>The Internal Secretion of the Pancreas</i> , 7 J. LAB. CLINICAL MED. 251 (1922)	Banting
Bell, <i>Hamster Preproglucagon Contains the Sequence of Glucagon and Two Related Peptides</i> , 302 NATURE 716 (1983)	Bell
U.S. Patent No. 6,514,500	Bridon
Dong, <i>Glucagon-Like Peptide-1 Analogs with Significantly Improved in vivo Activity</i> , in PEPTIDES: THE WAVE OF THE FUTURE (Michal Lebl et al. eds., 2001)	Dong
Drucker, <i>Enhancing Incretin Action for the Treatment of Type 2 Diabetes</i> , 26 DIABETES CARE 2929 (2003)	Drucker 2003
Giannoukakis, <i>CJC-1131 ConjuChem</i> , 4(10) CURRENT OP. IN INVESTIGATIONAL DRUGS 1245 (2003)	Giannoukakis
Gutniak, <i>Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36)Amide in Normal Subjects and Patients with Diabetes Mellitus</i> , 326 NEW ENG. J. MED. 1316 (1992)	Gutniak
HARRISON'S PRINCIPLES OF INTERNAL MED., Chapter 333 (Braunwald et al. eds. 15th ed. 2001)	Harrison's
Holst, <i>Truncated Glucagon-like Peptide I, an Insulin-Releasing Hormone from the Distal Gut</i> , 211 (2) FEBS LETTERS 169 (1987)	Holst
Holst, <i>The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism</i> , 53 (suppl. 3) DIABETES S197 (2004)	Holst 2004

**TABLE OF ABBREVIATIONS**  
(continued)

Full Name of Cited Reference	Abbreviation
Holst, <i>Glucagon-Like Peptide 1 and Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Type 2 Diabetes Mellitus</i> , 4 CURRENT OP. IN PHARM. 589 (2004)	Holst 2004b
Knudsen, <i>GLP-1 Derivatives as Novel Compounds for the Treatment of Type 2 Diabetes: Selection of NN2211 for Clinical Development</i> , 26(7) DRUGS OF THE FUTURE (2001)	Knudsen 2001
Knudsen, <i>Glucagon-Like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes</i> , 47(17) J. MED. CHEM. 4128 (2004)	Knudsen 2004
U.S. Patent No. 6,268,343	Knudsen patent
Madsbad, <i>Improved Glycemic Control with No Weight Increase in Patients with Type 2 Diabetes After Once-Daily Treatment with the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-Week, Double-Blind, Randomized, Controlled Trial</i> , 27 DIABETES CARE 1335 (2004)	Madsbad
Mojsov, <i>Insulintropin: Glucagon-like Peptide I (7-37) Co-encoded in the Glucagon Gene is a Potent Simulator of Insulin Release in the Perfused Rat Pancreas</i> , 79 J. CLINICAL INVESTIGATION 616 (1987)	Mojsov
Nauck, <i>Normalization of Fasting Hyperglycaemia by Exogenous Glucagon-Like Peptide 1 (7-36 amide) in Type 2 (Non-Insulin-Dependent) Diabetic Patients</i> , 36 DIABETOLOGIA 741 (1993)	Nauck
Ørskov, <i>Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects are Indistinguishable</i> , 42 DIABETES 658 (1993)	Ørskov
Polonsky, <i>What's So Tough About Taking Insulin? Addressing the Problem of Psychological Insulin Resistance in Type 2 Diabetes</i> , 22(3) CLINICAL DIABETES 147 (2004)	Polonsky
WO 91/11457	WO457

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.